In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

IVEN Shines at CPHI China 2025 IVEN logo IVEN factory SHANGHAI, SHANGHAI, CHINA, July 5, 2025 /EINPresswire / -- As the global p ...

Great ideas with syringe Subscribe! Donald Trump issues warning to AOC after impeachment push Tallulah Willis Responds to ...

The global drug delivery technology market is projected to be valued at USD 52.1 billion by 2025 and is expected to reach USD ...

Boehringer Ingelheim has launched Vetmedin (pimobendan) 1.5 mg/ml oral solution for dogs in Great Britain, offering a new ...

Never Events Never Events are serious, largely preventable patient safety incidents that should not occur if healthcare providers have implemented existing national guidance or safety recommendations.

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...